Group 1 - The core viewpoint of the report is that the rating of Giant Bio (02367) has been downgraded from "Buy" to "Neutral," with the target price reduced by 45% from HKD 64 to HKD 35 [1] - The company is facing multiple challenges, including a series of reputation crises and a double-digit decline in its core brand, Kefu Mei, during the Double Eleven shopping festival [1] - The report suggests that the investment logic for Giant Bio has shifted from growth to strategic adjustment, indicating a lack of clear catalysts for a rebound [1] Group 2 - The brokerage firm has lowered its revenue forecasts for 2025-2027 by an average of 30% to reflect the latest guidance from management and a more cautious outlook for 2026 [1] - The sales expense ratio forecast has been increased from 36% to 38% to account for execution challenges during the adjustment phase [1] - The target price is now based on a reduced price-to-earnings ratio of 16 times the 2026 forecast, down from the previous 21.5 times [1]